Introduction: With an incidence of approximately 2% in men in Brazil, Penile Cancer (PC) represents approximately 10% of cancer cases in the North region. PC has a multifactorial origin, being related to HPV, poor hygiene, smoking and others. PC is silent and painless, with its characteristic symptoms, which are caused by the presence of ulcers, vegetative or intraurethral lesions, occurring in more advanced stages, and may include bleeding, pain and odor. In underdeveloped regions, its incidence ends up being higher, generating social and economic impacts. Objectives: To analyze the epidemiological scenario of penile neoplasia in the North region of Brazil, from 2014 to 2024. Methods: This is an epidemiological study, with quantitative data obtained from the Ministry of Health – Outpatient Information System (SIA/SUS), referring to cases of penile cancer, diagnosed between 2014 and 2024. The case variables were studied by region and municipality of diagnosis, age group and staging, and these were tabulated using the Microsoft Office Excel® 2019 program for descriptive statistical analysis. Results: From 2014 to 2024, 706 cases of CP were diagnosed in the North region, with a sharp increase in 2020 and 2021, with the highest number of incidences, with 94 reported cases, totaling 188 cases (26.62%). The year 2014 was the year with the lowest incidence, with 23 cases (3.25%). Regarding the municipalities with the highest incidence, Belém (35.41%), Manaus (24.22%) and Porto Velho (20.39%) had the highest number. Regarding age, the largest affected group is between 60 and 64 years old (12.60%). When we analyze cancer staging, 13% are level 3 and 8.92% level 4, however 70.39% of notifications do not have staging, being ignored or not applicable, highlighting the fragility of having reliable data in the diagnostic phase. Conclusion: Data analysis allowed us to observe the number of cases diagnosed in the last ten years in the North region, highlighting the elderly male population, between the ages of 60 and 64, as the most affected, with their diagnosis made between stages 3 and 4 of the neoplasia. In this sense, epidemiological studies and data analysis are necessary to obtain effective regional strategies for prevention and screening of this condition.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
